Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

These cancers instead rely on the PARP repair pathway, making this back-up pathway a solid target for anti-cancer treatments. The key to building on this success for a wider range of cancers is ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell ...

By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer.

The trial focused on stenoparib, a novel dual PARP/Wnt pathway inhibitor, and its effectiveness in patients with platinum-resistant or refractory ovarian cancer. These patients typically have ...

By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer.

Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of ... repair defects with response to treatment with PARP inhibitors marked the first successful application ...

Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatmentFully funded by the U.S. Veterans’ Administration Special Emphasis Pane ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...